Previous close | 7.60 |
Open | 7.60 |
Bid | 0.00 x 0 |
Ask | 0.00 x 0 |
Day's range | 7.60 - 7.60 |
52-week range | 7.60 - 7.60 |
Volume | |
Avg. volume | N/A |
Market cap | 137.495M |
Beta (5Y monthly) | 1.44 |
PE ratio (TTM) | N/A |
EPS (TTM) | -0.37 |
Earnings date | N/A |
Forward dividend & yield | N/A (N/A) |
Ex-dividend date | N/A |
1y target est | N/A |
DGAP-News: BRAIN Biotech AG / Key word(s): SustainabilityBRAIN Biotech publishes first ESG and Sustainability Report 20.06.2022 / 08:00 The issuer is solely responsible for the content of this announcement.BRAIN Biotech publishes first ESG and Sustainability ReportZwingenberg, June 20, 2022 – BRAIN Biotech AG has published its first ESG and sustainability report. The company, which already directly addresses at least five UN Sustainable Development Goals (SDGs) with its products and solutions, s
DGAP-News: BRAIN Biotech AG / Key word(s): PersonnelBRAIN Biotech AG: Prof. Dr. Bernhard Hauer leaves Supervisory Board of BRAIN Biotech AG for personal reasons 30.05.2022 / 09:00 The issuer is solely responsible for the content of this announcement.Prof. Dr. Bernhard Hauer leaves Supervisory Board of BRAIN Biotech AG for personal reasonsZwingenberg, 30.05.2022 – Professor Dr. Bernhard Hauer has informed the Chairman of the Supervisory Board of BRAIN Biotech AG that he wishes to resign from his
DGAP-News: BRAIN Biotech AG / Key word(s): Half Year Results/Half Year ReportBRAIN Biotech AG: Ongoing Dynamic Sales Development and Rising Profitability, 6M Reporting 30.05.2022 / 07:30 The issuer is solely responsible for the content of this announcement.BRAIN Biotech AG: Ongoing Dynamic Sales Development and Rising Profitability, 6M Reporting Very positive growth trend confirmed by 20% organic expansion in Q2 Significant improvement in profitability, adjusted EBITDA positive Full fiscal year